Comparative cutoff points for adenosine monophosphate and methacholine challenge testing.

Area of Science:

• Pulmonary Medicine
• Respiratory Physiology
• Clinical Pharmacology

Background:

• The standard 20% cutoff for bronchial challenge tests (PC20) is unsuitable for patients with severe airflow obstruction.
• This limitation restricts the utility of bronchial provocation tests in a significant asthma patient population.

Purpose of the Study:

• To assess the efficacy and safety of reduced cutoff points (10% and 15%) for adenosine monophosphate (AMP) and methacholine (MCH) bronchial challenges.
• To determine if these lower thresholds can effectively monitor treatment response in chronic asthma patients.

Main Methods:

• Retrospective analysis of data from five prior studies involving AMP and MCH bronchial challenges.
• Recalculation of 10% and 15% cutoff points for AMP and MCH.
• Analysis of the correlation between single results and dose-shift changes following anti-inflammatory treatment.

Main Results:

• Strong correlations were observed between the 20% cutoff and lower thresholds (15% and 10%) for both MCH (PD20 vs. PD15: r=0.80; PD20 vs. PD10: r=0.65) and AMP (PC20 vs. PC15: r=0.96; PC20 vs. PC10: r=0.84).
• Doubling dose shifts after anti-inflammatory treatment (inhaled corticosteroids, montelukast) significantly correlated with these cutoff points.
• Subgroup analysis for AMP challenges post-inhaled corticosteroids confirmed strong correlations (PC20 vs. PC15: r=0.92; PC20 vs. PC10: r=0.84).

Conclusions:

• Lower cutoff points (10% and 15%) for AMP and MCH bronchial challenges reliably predict the 20% cutoff values.
• These reduced thresholds are suitable for monitoring therapeutic responses in asthma.
• Utilizing lower cutoff points minimizes patient exposure to provocation agents, enhancing safety.